Compare Stocks: IRD, ALVO, SVRA, and FBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$5.03 -4.2%	$3.68	$2.94 ▼ $9.25	$1.52B	0.18	675,212 shs	1.77 million shs
FBRX Forte Biosciences	$76.97 +0.0%	$50.43	$10.11 ▼ $77.20	$1.63B	2.6	676,028 shs	1.24 million shs
IRD Opus Genetics	$4.11 +2.0%	$3.76	$1.17 ▼ $5.81	$339.69M	0.59	932,839 shs	1.49 million shs
SVRA Savara	$5.60 +0.7%	$5.70	$3.10 ▼ $7.01	$1.15B	0.29	1.63 million shs	1.61 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+18.51%	+35.31%	+71.57%	+53.51%	-37.87%
FBRX Forte Biosciences	+0.04%	+0.08%	+40.47%	+250.73%	+573.23%
IRD Opus Genetics	-0.49%	+10.41%	+30.84%	-1.47%	+250.43%
SVRA Savara	-0.54%	+3.54%	+0.91%	+8.17%	+75.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$5.03 -4.2%	$3.68	$2.94 ▼ $9.25	$1.52B	0.18	675,212 shs	1.77 million shs
FBRX Forte Biosciences	$76.97 +0.0%	$50.43	$10.11 ▼ $77.20	$1.63B	2.6	676,028 shs	1.24 million shs
IRD Opus Genetics	$4.11 +2.0%	$3.76	$1.17 ▼ $5.81	$339.69M	0.59	932,839 shs	1.49 million shs
SVRA Savara	$5.60 +0.7%	$5.70	$3.10 ▼ $7.01	$1.15B	0.29	1.63 million shs	1.61 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+18.51%	+35.31%	+71.57%	+53.51%	-37.87%
FBRX Forte Biosciences	+0.04%	+0.08%	+40.47%	+250.73%	+573.23%
IRD Opus Genetics	-0.49%	+10.41%	+30.84%	-1.47%	+250.43%
SVRA Savara	-0.54%	+3.54%	+0.91%	+8.17%	+75.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.25	Hold	$7.50	45.21% Upside
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.87% Downside
IRD Opus Genetics	2.89	Moderate Buy	$10.69	150.70% Upside
SVRA Savara	2.88	Moderate Buy	$10.14	82.59% Upside

Current Analyst Ratings Breakdown

Latest IRD, ALVO, SVRA, and FBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	ALVO Alvotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	ALVO Alvotech	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/11/2026	IRD Opus Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	IRD Opus Genetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$10.00 ➝ $9.00
7/29/2026	IRD Opus Genetics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$74.00 ➝ $77.00
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$77.00
7/27/2026	FBRX Forte Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.95M	3.17	$0.25 per share	20.33	($0.94) per share	-5.49
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$4.71 per share	N/A
IRD Opus Genetics	$14.20M	24.82	N/A	N/A	$0.22 per share	19.39
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	$27.92M	-$0.61	N/A	16.14	N/A	-36.31%	-11.92%	-11.73%	11/11/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	-338.88%	-150.13%	11/11/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest IRD, ALVO, SVRA, and FBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	ALVO Alvotech	-$0.0526	-$0.11	-$0.0574	-$0.22	$103.00 million	$105.77 million
8/11/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.65	0.96
FBRX Forte Biosciences	N/A	10.01	10.01
IRD Opus Genetics	N/A	12.19	12.19
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
FBRX Forte Biosciences	77.63%
IRD Opus Genetics	14.97%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
FBRX Forte Biosciences	4.40%
IRD Opus Genetics	11.70%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,460	301.81 million	N/A	Not Optionable
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable
IRD Opus Genetics	14	82.65 million	72.98 million	N/A
SVRA Savara	20	205.46 million	194.57 million	Optionable

IRD, ALVO, SVRA, and FBRX Headlines

Recent News About These Companies

Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

August 25 at 5:43 AM | marketbeat.com

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

August 25 at 3:43 AM | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24 at 12:30 AM | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24 at 4:05 PM | businesswire.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 24 at 4:13 AM | marketbeat.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

HC Wainwright Issues Negative Outlook for Savara Earnings

August 16, 2026 | americanbankingnews.com

Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

August 15, 2026 | marketbeat.com

What is HC Wainwright's Estimate for Savara FY2029 Earnings?

August 15, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Lowered to Sell Rating by Wall Street Zen

August 15, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Brokers Lower Earnings Estimates for Savara

August 14, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Price Down 5.4% - What's Next?

August 13, 2026 | marketbeat.com

HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

August 13, 2026 | marketbeat.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 11, 2026 | marketbeat.com

Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC

August 8, 2026 | marketbeat.com

Savara (SVRA) to Announce Quarterly Earnings on Wednesday

August 5, 2026 | marketbeat.com

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

August 5, 2026 | seekingalpha.com

Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA

August 2, 2026 | marketbeat.com

Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRD, ALVO, SVRA, and FBRX Company Descriptions

Alvotech NASDAQ:ALVO

$5.03 -0.22 (-4.19%)

Closing price 04:00 PM Eastern

Extended Trading

$5.06 +0.03 (+0.60%)

As of 05:30 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Forte Biosciences NASDAQ:FBRX

$76.97 +0.02 (+0.03%)

Closing price 04:00 PM Eastern

Extended Trading

$76.97 +0.00 (+0.01%)

As of 04:20 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Opus Genetics NASDAQ:IRD

$4.11 +0.08 (+1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$4.22 +0.11 (+2.77%)

As of 05:24 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Savara NASDAQ:SVRA

$5.60 +0.04 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$5.68 +0.08 (+1.34%)

As of 05:05 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, ALVO, SVRA, and FBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, ALVO, SVRA, and FBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, ALVO, SVRA, and FBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, ALVO, SVRA, and FBRX Company Descriptions

Alvotech NASDAQ:ALVO

Forte Biosciences NASDAQ:FBRX

Opus Genetics NASDAQ:IRD

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, ALVO, SVRA, and FBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, ALVO, SVRA, and FBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, ALVO, SVRA, and FBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, ALVO, SVRA, and FBRX Company Descriptions

Alvotech NASDAQ:ALVO

Forte Biosciences NASDAQ:FBRX

Opus Genetics NASDAQ:IRD

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools